ArticleIs insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?L’insuline détémir peut-elle favoriser une plus faible variabilité d’action de l’insuline injectée chez les patients diabétiques ?
References (19)
- et al.
Reproducibility and variability in the action of injected insulin
Diabetes Metab.
(2005) - et al.
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen
Clin Ther.
(2004) - et al.
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes
Diabetes Res Clin Pract.
(2004) Design of insulin analogs for meal-related therapy
J Diabetes Complic.
(1993)- et al.
Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study
Diabetes Care
(2000) - et al.
The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption
Diabet Med.
(1988) - et al.
Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart
Diabetes Care
(1988) - et al.
Mode of action of fatty acid acylated insulin: a novel type of soluble, long-acting insulin analogues
Diabetes
(1996) - et al.
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
Diabet Med.
(1999)
There are more references available in the full text version of this article.
Cited by (14)
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis
2008, Diabetes Research and Clinical PracticeCitation Excerpt :Basal insulin can be provided using either NPH human insulin or long-acting insulin analogues. Analogues, which are more expensive than NPH insulin, should warrant a greater reproducibility of absorption after subcutaneous injection, providing better metabolic control with reduced hypoglycemic risk [1,2]. A recent meta-analysis of eight randomized clinical trials failed to detect any difference in HbA1c, while confirming an advantage with regard to incidence of hypoglycemia [3].
Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years
2020, British Journal of Clinical PharmacologyComparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999–2013 in Taiwan
2018, British Journal of Clinical PharmacologyClinical safety of insulin detemir in patients with Type 2 diabetes in the Gulf countries: The multicenter, noninterventional, open-label LevSafe study
2016, Indian Journal of Endocrinology and MetabolismComparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients
2013, International Journal of Endocrinology
Copyright © 2005 Elsevier Masson SAS. All rights reserved.